WILMINGTON, DE — Incyte (Nasdaq: INCY) has announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from May 30 to June 3. The presentations will feature findings from both its approved therapies and early-stage pipeline, offering insights into advancements in treating difficult cancers and hematological diseases.
“The data featured at the 2025 ASCO Annual Meeting, from both our approved medicines and early-stage pipeline, reflect our ongoing efforts to transform cancer care,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte. “We are advancing potential therapies across some of the most difficult-to-treat cancers and hematological diseases, including squamous cell anal cancer, ovarian cancer, and myelofibrosis, with the hope of making a meaningful difference for these patients.”
Key Presentations
Among the highlights are oral and poster presentations addressing innovative approaches to cancer treatment.
Oral Sessions
- INCB123667 (June 3): A Phase 1 trial evaluating the safety and preliminary efficacy of this CDK2 inhibitor in patients with advanced platinum-resistant ovarian cancer will be presented.
- Pemigatinib (May 30): Results from a Phase 2 study on its use in glioblastoma and gliomas with FGFR1-3 alterations will be showcased.
Poster Presentations
- Retifanlimab (May 31 – June 1): Multiple studies, including research on HIV-related squamous cell carcinoma of the anal canal and long-term outcomes in Merkel cell carcinoma, will spotlight the potential of this PD-1 antibody.
- INCB123667 & INCB057643 (June 1): Additionally, data on the efficacy of INCB123667 in endometrial cancer and the use of INCB057643, a BET inhibitor, in treating relapsed or refractory myelofibrosis will be shared.
Advancing Cancer Care
These findings reinforce Incyte’s commitment to developing innovative therapies aimed at improving outcomes for patients with challenging cancers. From ovarian cancer to hematological malignancies, the company’s focus spans a diverse range of diseases, underlining its pledge to address unmet needs in oncology.
By delivering comprehensive data and novel therapeutic insights, the research showcased at ASCO 2025 highlights the potential of emerging treatments to transform cancer care. Looking forward, these advancements could pave the way for significant improvements in how some of the most complex cancers are treated, offering new hope for patients and their families.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.